FAQ on Quantum BioPharma Ltd.'s Appointment of Kevin Malone as Board Advisor
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) has appointed Kevin Malone, a seasoned financial advisor and anti-corruption advocate, as an advisor to its Board of Directors, aligning with the company's shareholder protection values and therapeutic focus.
Who is Kevin Malone and what is his background?
Kevin Malone is a seasoned financial advisor with over 40 years of family experience in wealth management, known for his work in market pattern recognition and his outspoken stance against trading manipulation. He is the founder of Malone Wealth and champions financial literacy and advocates against naked short selling.
Why did Quantum BioPharma appoint Kevin Malone as a Board Advisor?
Quantum BioPharma appointed Kevin Malone due to his expertise in financial markets and his advocacy against trading manipulation, which aligns with the company’s shareholder protection values and its focus on developing therapeutic solutions for challenging disorders.
What is Quantum BioPharma Ltd. focused on?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Lucid-MS and who is developing it?
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It is being developed by Lucid Psycheceuticals Inc., a wholly owned subsidiary of Quantum BioPharma.
What is UNBUZZD and how is Quantum BioPharma involved with it?
UNBUZZD is a product invented by Quantum BioPharma, which spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains ownership of 25.71% of Celly Nutrition and receives royalty payments from sales of UNBUZZD.
Where can I find more information about Quantum BioPharma and its latest updates?
The latest news and updates relating to Quantum BioPharma (QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.
What are the terms of the agreement between Quantum BioPharma and Celly Nutrition regarding UNBUZZD?
The agreement includes royalty payments of 7% of sales from UNBUZZD until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
What is InvestorWire and how is it related to Quantum BioPharma?
InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication for private and public companies, including Quantum BioPharma, as part of the Dynamic Brand Portfolio within the InvestorBrandNetwork.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119896